Few controlled trials compared second-generation antipsychotics (SGAs) with first-generation antipsychotics (FGAs) regarding relapse prevention in schizophrenia. We conducted a systematic review/meta-analysis of randomized trials, lasting X6 months comparing SGAs with FGAs in schizophrenia. Primary outcome was study-defined relapse; secondary outcomes included relapse at 3, 6 and 12 months; treatment failure; hospitalization; and dropout owing to any cause, non-adherence and intolerability. Pooled relative risk (RR) ( ± 95% confidence intervals (CIs)) was calculated using random-effects model, with numbers-neededto-treat (NNT) calculations where appropriate. Across 23 studies (n = 4504, mean duration = 61.9 ± 22.4 weeks), none of the individual SGAs outperformed FGAs (mainly haloperidol) regarding study-defined relapse, except for isolated, single trial-based superiority, and except for risperidone's superiority at 3 and 6 months when requiring Z3 trials. Grouped together, however, SGAs prevented relapse more than FGAs (29.0 versus 37.5%, RR = 0.80, CI: 0.70-0.91, P = 0.0007, I 2 = 37%; NNT = 17, CI: 10-50, P = 0.003). SGAs were also superior regarding relapse at 3, 6 and 12 months (P = 0.04, P < 0.0001, P = 0.0001), treatment failure (P = 0.003) and hospitalization (P = 0.004). SGAs showed trend-level superiority for dropout owing to intolerability (P = 0.05). Superiority of SGAs regarding relapse was modest (NNT = 17), but confirmed in double-blind trials, first-and multi-episode patients, using preferentially or exclusively raw or estimated relapse rates, and for different haloperidol equivalent comparator doses. There was no significant heterogeneity or publication bias. The relevance of the somewhat greater efficacy of SGAs over FGAs on several key outcomes depends on whether SGAs form a meaningful group and whether mid-or low-potency FGAs differ from haloperidol. Regardless, treatment selection needs to be individualized considering patient-and medication-related factors.
Introduction
As psychopathology and social functioning can worsen with repeated relapses in schizophrenia patients, 1 relapse prevention is a critical issue in managing this illness. Since clozapine, the first second-generation antipsychotic (SGA) introduced in 1971 (marketed in the United States of America in 1990), and risperidone, introduced in 1994, a total of eight additional SGAs are now available in the United States of America, which are widely used. 2 SGAs are better tolerated than first-generation antipsychotics (FGAs) regarding acute extra-pyramidal side effects (EPS) 3 and tardive dyskinesia. 4 However, there is growing concern about metabolic side effects, such as body weight gain, insulin resistance and dyslipidemia. 5, 6 Combined with the lack of significant superiority in efficacy and/or effectiveness observed in large, pragmatic trials, 7-10 the advantages of non-clozapine SGAs over FGAs have been challenged. Less attention has been focused on relapse prevention. A meta-analysis comparing SGAs to FGAs was published in 2003, 11 but since then, there have been 12 additional relevant trials.
Materials and methods

Search
We conducted a search using MEDLINE/PubMed, the Cochrane library and PsycINFO (last search date January 2011) for randomized, controlled trials of relapse prevention or maintenance treatment of schizophrenia and related disorders lasting X6 months. Studies had to be published in English in peer-reviewed journals. Search terms included antipsychotic(s); neuroleptic(s); individual names of SGAs and FGAs; schizophrenia; random, randomly, randomized; and maintenance, relapse or long-term. The electronic search was supplemented by hand search of reference lists of relevant studies and reviews. Authors and companies were contacted to provide missing information and unpublished data.
Inclusion criteria
The trials included in this analysis were randomized, head-to-head comparisons of oral SGAs versus oral FGAs for relapse prevention or maintenance treatment in adults with schizophrenia. We only included trials with a minimum duration of 6 months (one study included patients with a range of 22-84 weeks' completion 12 ). We also only included trials providing relapse-related information, such as study-defined relapse or re-hospitalization. Trials were included irrespective of whether randomization occurred during the acute or maintenance phase. However, when patients were randomized in the acute phase, we only used data from patients for whom information was available after they had responded, remitted or were discharged.
Data extraction and outcomes
Data were extracted independently by X2 reviewers (T Kishimoto, V Agarwal, T Kishi, CU Correll) . Any disagreements were resolved by consensus.
The primary outcome measure was study-defined relapse at endpoint, preferentially based on survival curves, which we believe yield more accurate data for relapse than raw relapse rates, as the bias of unequal follow-up duration is minimized. If the estimated relapse rate was not available, we used raw relapse rate. Although we used study-defined relapse, when there was no definition of relapse or the authors' definition was regarded as inappropriate, we used the next most appropriate outcome for our analysis, which predominantly was re-hospitalization.
As secondary outcomes, relapse rates at 3, 6 and 12 months; 'treatment failure' (defined as relapse and/or all-cause discontinuation, depending on whether data were available for both outcomes); hospitalization; and dropout owing to any cause, non-adherence and intolerability were examined.
Data analysis
All outcomes were dichotomous and SGAs were compared to FGAs both individually and as separate groups for each outcome. As a general rule, we applied a ''once-randomized-analyzed'' endpoint analysis.
Modifications to this rule included studies in which only patients reaching the maintenance phase were considered at risk for relapse and studies where the population entered into the Kaplan-Meier survival curves did not include all originally randomized patients. Pooled relative risk (RR) ( ± 95% confidence intervals (CIs)) and risk differences were calculated using random-effects models by DerSimonian and Laird, 13 which is more conservative than fixed-effects models. Number-needed-to-treat (NNT) was calculated where appropriate. To reduce a potential type-I error, we considered the meta-analytic results to be significant only if they were based on X3 studies.
Heterogeneity between studies was explored with a w 2 -test of homogeneity (P < 0.1) together with the I 2 -statistic, with I 2 Z50% indicating significant heterogeneity. 14 In addition to the primary and secondary outcome analyses, we also conducted a priori defined sensitivity analyses of the primary outcome comparing SGAs with FGAs, seeking to identify potential methodological biases and whether the findings extended to clinically relevant sub-populations and treatment groups. The examined variables included (a) treatment concealment (open versus blinded); (b) sponsorship (industry versus academia); (c) publication year (before 2000 versus 2000 and later); (d) clozapine versus non-clozapine SGAs; (e) randomization time point (acute versus maintenance phase); (f) determination of patient stability (X4 weeks versus < 4 weeks); (g) first-versus multi-episode patients; and (h) haloperidol equivalent comparator dose level ( < 5 versus X5 mg and < 10 versus X10 mg), calculated for non-haloperidol medications using established conversion factors. 15 We also assessed the generalizability of the primary outcome results, using alternative ways to calculate relapse, that is, using preferentially raw over estimated relapse rates, and using only raw or estimated rates instead of preferring estimated relapse rate. Finally, to test whether the results could be reversed in favor of FGAs, we performed a 'best case scenario' analysis for FGAs. We pooled all studies where the RR for study defined relapse was Z1.0, or > 1.0, that is, we excluded all studies where SGAs had any effect (significant or non-significant) that was larger than for FGAs.
All data were entered into a funnel graph (trial effect against trial size) to investigate the likelihood of overt publication bias. 16 Data were double-entered (T Kishimoto, V Agarwal) into Review Manager 5.0.25, a program developed by the Cochrane Collaboration for systematic reviews.
Results
Search and study characteristic
We included 18 publications of 23 randomized, active drug-controlled studies with 4504 participants ( Supplementary Figure 1) .
The number of participants per study ranged from 32 to 690 (median: 147) and mean maximum study (2) X20% deterioration in BPRS-T;
(3) discontinuation owing to lack of efficacy or non-compliance; (4) (Table  1) . There were six studies with first-episode and 17 with multiple-episode patients.
Five studies were open-label, 17 were double-blind and one study was rater-masked. 17 The number of studies with each individual SGA was as follows: amisulpride = 3, aripiprazole = 2, clozapine = 4, iloperidone = 3, olanzapine = 6, quetiapine = 1, risperidone = 6, sertindole = 1, and ziprasidone = 1. Haloperidol was the comparator in 21/23 studies; one study used chlorpromazine; 26 and one used mixed FGAs. 18 Mean haloperidol equivalent dose was 11.6 ± 8.3 mg day À1 (range: 2.9-28.5). Eighteen studies (78.3%) randomized patients in the acute phase and only five studies (21.7%) randomized patients in the maintenance phase. Eight studies (34.8%) determined patients' stability for X4 weeks and 15 studies (65.2%) determined patients' stability < 4 weeks or cross-sectionally. Relapse definitions varied. In nine studies, relapse was not defined. In four of these, 10, 18, 20, 26 we used hospitalization rate. In the remaining five, we used 'failure to maintain response', 25 'psychotic exacerbation', 27 'failed to maintain improvement' 21 and 'dropout owing to decompensation'. 17 In another study, very strict, pre-defined relapse criteria resulted in no relapse in either group. 31 Therefore, the authors employed 'marked clinical deterioration' post hoc, which we also used.
Endpoint relapse rate
Two single studies of SGAs yielded significant superiority over FGA. These included sertindole (n = 203, RR = 0.29, CI: 0.10-0.84, P = 0.02) and ziprasidone (n = 66, RR = 0.35, CI: 0.16-0.79, P = 0.01). When requiring X3 trials per individual antipsychotic, neither risperidone (n = 1124, RR = 0.75, CI: 0.56-1.00, P = 0.05, I 2 = 55%), clozapine (n = 355, RR = 0.72, CI: 0.47-1.10, P = 0.12 I 2 = 0%) or olanzapine (n = 1140, RR = 0.88, CI: 0.70-1.10, P = 0.27, I 2 = 22%) was statistically superior to FGAs in preventing relapse (Figure 1 ). However, when grouped together, SGAs were significantly superior to FGAs without significant heterogeneity (N = 19, n = 4206, 29.0 versus 37.5%, RR = 0.80, CI: 0.70-0.91, P = 0.0007, I 2 = 37%; NNT = 17, CI: 10-50, P = 0.003) (Figure 1 ).
Relapse rate at 3, 6 and 12 months
Several individual SGAs were associated with significantly lower relapse rates at specific time points. This included clozapine at 3 months (P = 0.03), 6 months (P = 0.006), olanzapine at 6 months (P = 0.0003) and sertindole (P = 0.02) as well as ziprasidone (P = 0.01) at 12 months. Requiring X3 analyzable trials, only risperidone showed significant superiority over FGAs at both 6 months (P = 0.004) and 12 months (P < 0.0001) ( Supplementary Figures  2-4 ). Pooled SGAs, however, were superior to FGAs at all pre-specified time points, that is, 3 months: 13.8 versus 17.4%, P = 0.04; 6 months: 21.0 versus 28.1%, P < 0.0001; 12 months: 31.4 versus 37.1%, P = 0.0001. Treatment failure; hospitalization; and dropout owing to any cause, non-adherence and intolerability Individually, only olanzapine was superior to FGAs (P = 0.03) regarding treatment failure defined as relapse and/or all-cause discontinuation, but pooled together, SGAs significantly outperformed FGAs (P = 0.003) (Figure 2) . Except for single-study superiority of sertindole and ziprasidone (P = 0.03 each), none of the individual SGAs was superior to FGAs in preventing hospitalization (Figure 3 ). However, pooled together, SGAs were superior to FGAs (12.1 versus 16.9%, P = 0.004).
Dropout rates for reasons other than relapse varied widely from 9.1 to 68.2% (median: 34%, 13 studies with data). Except for single study-based lower dropout for non-adherence with sertindole (P = 0.02), no significant superiority was found for any individual SGA for dropout owing to any reason, nonadherence or intolerability. Even when pooled together, SGAs had only trend-level superiority over FGAs regarding dropout owing to any cause (P = 0.06) ( Supplementary Figure 5) , non-adherence (fewer data points were available, P = 0.20) ( Supplementary Figure 6 ) and intolerability (P = 0.05) ( Supplementary  Figure 7) .
Sensitivity and subgroup analyses
The superiority of grouped SGAs regarding prevention of relapse remained significant in blinded studies (N = 18, n = 3519, P = 0.003), pharmaceutical companysponsored studies (N = 15, n = 3250, P < 0.00001), studies published before and after 2000 (N = 8, n = 1282, P = 0.0002, and N = 14, n = 2774, P = 0.03, respectively), non-clozapine SGA studies (N = 18, n = 3701, P = 0.002), both randomization time points (acute phase: N = 17, n = 3326, P = 0.001; maintenance phase: N = 5, n = 730, P < 0.00001), studies with < 4 weeks or cross-sectionally assessed stability (N = 14, n = 2454, P = 0.0006), and in first-and multi-episode patients (N = 6, n = 1207, P = 0.02, and N = 16, n = 2849, P = 0.0009, respectively) ( Table 2) . Results remained significant regardless of the haloperidol comparator dose ( < 5 mg/day, N = 7, N = 1187, P = 0.01; X5 mg/day, N = 15, n = 2869, P = 0.003; < 10 mg/day, N = 10, n = 1963, P = 0.007; X10 mg/day, N = 12, n = 2093, P = 0.006). Academia-sponsored studies (N = 6, n = 767, P = 0.05) and studies requiring validated patient stability for X4 weeks showed trend-level superiority of SGAs (N = 8, n = 1602, P = 0.08) ( Table 2) .
SGAs remained significantly superior over FGAs independent of whether raw relapse rates were used preferentially over estimated relapse rates (P = 0.005), and whether only estimated rates or raw rates were used (P = 0.0003 and P = 0.02, respectively) ( Table 2) . Finally, performing a 'best case scenario' analysis for FGAs, we pooled all studies where the RR for studydefined relapse was Z1.0. In this subsample, SGAs were not inferior to FGAs (N = 9, n = 836, RR = 1.08, CI: 0.97-1.35, P = 0.50, I 2 = 0%). The same was true when removing the two studies with an RR = 1.0, that is, when analyzing only studies that had an RR > 1.0 that 
Other outcomes
Changes in psychopathology and side effects could not be formally meta-analyzed, as most studies did not provide these data separately for the stabilized subgroup in which relapse was examined.
Publication bias
The symmetrical funnel plot did not suggest overt publication bias ( Supplementary Figure 8) .
Discussion
This is the largest meta-analysis to date directly comparing relapse rates in schizophrenia patients treated with SGAs or FGAs followed for X6 months. We found that, whereas in some single studies individual SGAs were associated with significantly lower relapse rates and isolated other superiority regarding secondary outcomes, this was no longer the case when requiring at least three studies providing data for meta-analysis of individual drug effects. The exception was risperidone, which showed significant superiority over FGAs at both 6 months (P = 0.004) and 12 months (P < 0.0001) when requiring X3 analyzable trials. Of note, however, there was no instance where individual FGAs were superior to individual SGAs, either at a trial level or compared with all trials with a specific SGA. Moreover, when grouped together, SGAs as a group were superior to FGAs. Although the NNT of 17 is modest, the results were bolstered in that they were confirmed in a number of relevant sensitivity and subgroup analyses, and also extended to overall treatment failure and hospitalization, the latter of which is known to be less sensitive than relapse. 34 Therefore, we consider these findings are relevant when choosing long-term treatments in clinical practice. Although SGAs were not significantly superior to FGAs regarding all-cause discontinuation, discontinuation for intolerability or nonadherence, results trended in favor of SGAs (P = 0.05-0.20), and the analyzable samples for these outcomes included only 18-50% of all patients. However, these results need to be considered in the context of the cost-effectiveness discussion regarding SGAs versus FGAs. 9, [35] [36] [37] Our report included 23 studies, involving 4504 participants. This extends the similar findings from the earlier meta-analysis 11 that included 11 studies with 2032 patients. The inclusion criteria and methodology were similar, except that we preferred survival curve-estimated relapse rates over raw rates as our primary outcome, which we believe is a better measure as the shorter follow-up durations often found with FGAs can bias the results against SGAs, which often have a longer follow-up and observation duration during which relapse can occur. Actually, in both the prior and current meta-analyses, differences were smaller when raw relapse rates were used, but the results were not affected by the methods used to calculate relapse. Furthermore, compared with the prior meta-analysis, 11 we were able to include four additional SGAs in our analyses, that is, aripiprazole, iloperidone, quetiapine and ziprasidone; we included six first episode studies; and we were able to extend the analyses by investigating multiple secondary outcomes and conducting previously unavailable sensitivity analyses that confirmed and extended the primary results. This included superiority of SGAs compared with FGAs dosed below 5 mg/day (haloperidol equivalents), whereas the comparatively high haloperidol doses used in the earlier studies had been a major shortcoming in the previously available data base.
Nevertheless, relapse rates were substantially different between prior and current analyses, even when taking into account that we preferentially used survival analyses-based rates. In the prior analysis, 11 relapse rates at 1 year were 15 versus 23% for SGAs and FGAs compared with 31.4 versus 37.1% in our analysis. It appears that the low threshold definition of relapse in some more recent, large trials accounts for this difference, but SGAs demonstrated superiority regardless of whether study-defined relapse, treatment failure or hospitalization was used.
There has been much recent debate about the relative merits of SGAs over FGAs. [8] [9] [10] [36] [37] [38] [39] [40] Increasingly, the heterogeneity of SGAs and FGAs with need for individualization of treatment is being stressed. 8, [35] [36] [37] [38] [39] Nevertheless, different drug classes are usually determined by distinctly different mechanisms, and SGAs and FGAs differ regarding potentially relevant receptor-binding profiles. Moreover, the grouping has some historical relevance because of previous reviews and clinical trials of efficacy, effectiveness, relapse, EPS and tardive dyskinesia. Although we think the strict dichotomy has outlived its usefulness, we now have a larger series of studies comparing SGAs with haloperidol (once the leading drug worldwide), suggesting that there are modest differences regarding relapse prevention, a prevailing long-term goal in schizophrenia, regardless of high, medium or low haloperidol comparator dose, and, possibly, dropout owing to intolerability and non-adherence. The fact that we found relatively consistent differences favoring SGAs, although modest, also has heuristic implications in that some patients relapse despite adequate dopamine antagonism provided by FGAs and SGAs. Therefore, an understanding of what other mechanisms might be relevant for relapse (even in a subset of patients) is important.
However, the results of this study have to be interpreted in the context of several limitations. The data base, although larger than in the previous metaanalysis, is still limited, especially regarding individual SGAs as well as FGA comparators other than haloperidol. This limitation does not allow for a conclusive comparison of individual SGAs, which needs to be addressed by conducting additional studies. Another important limitation is the inconsistent definition of relapse. As noted, we used each study-defined relapse measure, and if no definition of relapse was available, or if the study-defined relapse criteria were considered inappropriate, we used what we judged to be the most appropriate relapse-related outcome, that is, predominantly psychiatric hospitalization. The problem of heterogeneously defined relapse is not surprising, as there is no universally accepted definition. On the other hand, this heterogeneity and broad-based definition of the primary outcome could also serve to enhance the generalizability of the results.
A further limitation is the methodological variability of the studies. For example, in many trials randomization occurred in the acute phase. To deal with this problem, we only used the subpopulation of patients who were judged to be responders or who were stable enough to be discharged, so that this subpopulation could be considered 'at risk' for relapse, having demonstrated clear improvement as well as subsequent, clear exacerbation from that new baseline state. The concern is that by including studies, which randomized acutely exacerbated patients, we would include only patients at risk for relapse who had responded to that specific medication for acute treatment. This could lead to a selection bias toward patients who experienced less side effects or experienced more improvement on the allocated medication. If we were limited to studies randomizing patients in the maintenance phase, only five studies would have been eligible for this metaanalysis. Furthermore, we also wanted to use the same inclusion criteria as in the previous metaanalysis. 11 Moreover, this apparent bias applied to both SGAs and FGAs, and mirrors clinical practice, in that maintenance treatment is used in patients who tolerate a given treatment and who do reasonably well on it.
Another limitation is the paucity of available data on potentially relevant factors, such as EPS and adherence, as well as the use of the high-potency FGA haloperidol in 21/23 studies, which precluded subgroup analyses for mid-or low-potency FGAs. The possibility that higher EPS rates could contribute to the higher rate of relapse, either directly or indirectly through non-adherence, should be considered. For example, the possibility exists that akathisia or severe akinesia might have mimicked or contributed to apparent psychotic exacerbation. However, it is unlikely that in a maintenance study involving relatively stable patients, there would be a sufficiently sudden or dramatic increase in EPS to trigger a clinical or rating-scale threshold of relapse. This is of particular importance because haloperidol was a comparator in most studies and therefore might have facilitated an apparent advantage for SGAs owing to its higher EPS risk. However, SGAs were superior regardless of the haloperidol comparator dose. There were insufficient data to conduct a meta-analysis on EPS or adherence, but in the studies with data, 17, 19, 20, 23, 31, 32 SGAs showed either significant or trend-level superiority in some of the EPS-related outcomes. Some studies provided non-adherence rates and some provided data on discontinuation for non-adherence, but these measures were generally crude. Nevertheless, we did not find significantly more non-adherence with FGAs in the nine studies with relevant data. In addition, other studies have not consistently shown that adherence with SGAs is sufficiently superior to explain the differences in relapse rates observed in our meta-analysis. 41, 42 Assuming that we have identified a true difference between SGAs and FGAs for relapse prevention, unconfounded with differences in adherence or EPS, possible explanations for this finding deserve consideration. Differences in receptor-biding profiles might have some role in relapse prevention. Clearly dopamine receptor antagonism alone is insufficient to prevent all relapses as evidenced by the roughly 20% of patients who relapse within a year on long-acting injectable antipsychotics. 43 It is possible that SGAs are associated with less dopamine receptor upregulation (as evidenced by lower rates of tardive dyskinesia 4 ) and that this might also impact rates of psychotic relapse. At the same time, SGAs have outperformed FGAs on measures of subjective well-being and quality of life, raising the possibility that these might also be mediating factors in relapse risk. 44 However, a detailed discussion of these possibilities is beyond the scope this report.
Finally, we acknowledge that other long-term costs of FGA and SGA treatment, such as the risk for tardive dyskinesia 4, 45 and for cardiovascular adverse effects, 6, [46] [47] [48] [49] require careful consideration in the individualized choice of treatments for schizophrenia patients.
Thus, although the results might appear somewhat confusing in that only several individual SGAs separated from the FGA comparator, whereas in pooled analyses SGAs were clearly superior to FGAs, we believe that our results indicate that this disconnect is likely due to a lack of power. This interpretation of the results is based on the following: First, despite inclusion of heterogeneous SGAs and study populations, there is no evidence that FGAs are superior to SGAs. Even when we restricted the analyses removing all individual studies that showed results in the direction of favoring SGAs (that is, best case scenario for FGAs in that all RRs were Z1.0 or > 1.0), the P-value for the comparison of these 9 and 7 studies was 0.50 and 0.43, respectively. Second, the superiority of combined SGAs versus FGAs was widespread, generalizing to almost all examined efficacy outcomes.
In conclusion, results from this meta-analysis suggest that, whereas individually SGAs were not consistently superior to FGAs, as a group, SGAs were associated with less study-defined relapse, overall treatment failure and hospitalization than FGAs, having a modest but clinically relevant effect size. Future relapse prevention studies should carefully assess EPS and adherence. Moreover, additional studies with a variety of SGAs using non-haloperidol FGA comparators at low-medium doses that do not produce significantly greater EPS than SGAs 47 are needed to extend these findings. In particular, sufficiently large data sets are needed to allow examination of the relative merits of individual SGAs, and to guide an individualized and evidence-based maintenance treatment selection in schizophrenia.
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